PALB2 and neoplasm: Afterwards, sensitivity to PARPi has been proved in tumor with loss of other tumor suppressor DNA repair proteins (e.g., ATR, ATM, RAD51, CHEK1/2, and PALB2), suggesting the validity of this therapeutic strategy also in patients intrinsically deficient in HR without BRCA1/2 mutations (54–57).